Abstract LB001: Anti-tumor activity and tolerability of the SHP2 inhibitor RMC-4630 as a single agent in patients with RAS-addicted solid cancersMarianna Koczywas, Sai‐Hong Ignatius Ou, Susanna V. Ulahannan et al.|Cancer Research|2021Cited by 16
Abstract LB054: Confirmation of target inhibition and anti-tumor activity of the SHP2 inhibitor RMC-4630 via longitudinal analysis of ctDNA in a phase 1 clinical studyJosie Hayes, Eric B. Haura, Marianna Koczywas et al.|Cancer Research|2021Cited by 4